Literature DB >> 3039049

Studies on DNA topoisomerases I and II in herpes simplex virus type 2-infected cells.

A R Bapat, F S Han, Z C Liu, B S Zhou, Y C Cheng.   

Abstract

It has been suggested that herpes simplex virus (HSV) type 1 may induce a virus-specific DNA topoisomerase activity which copurifies with virus-induced DNA polymerase. We have examined DNA topoisomerase (TOPO) I and II activities in HSV-2-infected HeLa S3 cells. Both activities were partially purified using DEAE-cellulose, phosphocellulose and double-stranded DNA cellulose column chromatography. It was found that both activities could be separated from HSV-2-specific DNA polymerase. Throughout the purification TOPO I could be immunologically detected with a monoclonal antibody developed against human TOPO I. Regardless of the source, mock- or HSV-2-infected human cells, both types of topoisomerase were equally tolerant of 200 mM-KCl. There appeared to be no apparent heterogeneity of TOPO I in HeLa S3 cells through the course of the HSV-2 infection. We conclude that host cell topoisomerases are quite stable in HSV-2-infected HeLa S3 cells and that there is no evidence that HSV-2 is capable of inducing HSV-2-specific TOPO I and TOPO II activities.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3039049     DOI: 10.1099/0022-1317-68-8-2231

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  3 in total

1.  Role of DNA topoisomerase I in the replication of herpes simplex virus type 2.

Authors:  Y Yamada; N Yamamoto; K Maeno; Y Nishiyama
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

2.  Human topoisomerase 1 messenger RNA is not destabilized by the herpes simplex virus type 2 virion-associated shut-off function.

Authors:  K F Bastow; B S Zhou; Y C Cheng
Journal:  Virus Genes       Date:  1989-08       Impact factor: 2.332

3.  Lack of in vitro antiviral activity of fluoroquinolones against herpes simplex virus type 2.

Authors:  A Pessina; E Mineo; L Gribaldo; M G Neri
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.